Copyright
©The Author(s) 2021.
World J Diabetes. Dec 15, 2021; 12(12): 1979-1999
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.1979
Published online Dec 15, 2021. doi: 10.4239/wjd.v12.i12.1979
Table 1 Summary of studies on modulation of thioredoxin interacting protein using natural antioxidants animal models
Ref. | Treatment | Animal model | Main findings |
[1] | Taohong Siwu decoction 18, 9 and 4.5mg/kg | Rat with middle cerebral artery occlusion | Improved neubehavioral function and inflammation and inhibited pyroptosis following ischemic stroke |
Intragastric administration for 7 d | |||
[2] | Z-Guggulsterone, 12.5, 25, 50 mg/kg, (ip) | Rat with middle cerebral artery occlusion | Z-Guggulsterone improved neurological deficit and, modulated redox imbalance and inflammation through inhibition of TXNIP/NLRP3 signaling |
Intraperitoneal administration for 6 d | |||
[11] | Curcumin 50 mg/kg, | Rat with cerebral artery occlusion | Attenuated ischemic brain injury. Modulation of TXNIP/NLRP3 inflammasome activation by suppression of ER stress. |
One hour before surgery, (ip) | |||
[70] [69] | Curcumin | HFD/ High sugar diet | Prevented fatty liver via inhibition of TXNIP |
[66] | Qurecetin | diabetes | Prevented inflammation, liver TXNIP, lipid accumulation |
[6] | Ketogenic diet | Mouse model of middle cerebral artery occlusion | Ketogenic diet improved ischemic tolerance, Attenuated ER stress and TXNIP/NLRP3 activation |
3 wk | |||
[7] | Umbelliferone, 15and 30 mg /kg | Rat with middle cerebral artery occlusion | Protected against cerebral ischemia reperfusion injury by suppressing TXNIP/NLRP3 inflammasome activation |
Pretreatment for 7 d (ip) | |||
[8] | Ruscogenin, 10 mg/kg One hour before surgery, (Intra gastic admin. | Mice with middle cerebral artery occlusion | Decreased brain infarction, edema, improved neurological outcome by suppressing a TXNIP/NLRP3 inflammasome activation and MAPK pathway |
[9] | Resveratrol, 5 mg/Kg | WT mice with embolic middle cerebral artery occlusion | Protected from ischemic injury, improved neurological score suppressed TXNIP/NLRP3 inflammasome and apoptosis |
3 h post-embolic occlusion. (iv) | |||
[21] | Salvianolic acid | HFD- Rats | Prevented HFD-induced NAFLD |
[65] | Salidroside | Prevented HFD-induced NAFLD | |
[12] | Compound 10b, 3 mg/kg | Rat with middle cerebral artery occlusion | Attenuated cerebral ischemia by upregulating endogenous antioxidant system and down regulation of oxidative stress. |
At the onset of reperfusion |
Table 2 Summary of studies on modulation of thioredoxin interacting protein expression using drug repurposing in animal models
Ref. | Treatment | Animal model | Main findings | |
[84] | Verapamil (0.15 mg/kg), intra venous | 1 h | Hyperglycemic mouse model middle cerebral artery occlusion | Reduced infarct area, hemorrhagic transformation and blood brain barrier damage. Improved stroke outcome and neuro inflammation in response to hyperglycemic stroke |
[7] | Verapamil po | 1 h | NMDA- optic neuropathy | Improved retinal neurodegeneration by altering antioxidant status and disrupting the Trx-ASK-1 inhibitory complex |
[67] | Verapamil, 25 mg/kg/d, IP | 1 wk | high-fat diet-induced obesity- 10 wk | Improved hepatic inflammation, metabolic homeostasis in NAFLD via TXNIP-NLRP3 inflammasome activation |
[104] | Verapamil | High-fat diet-prediabetic neuropathy | improved prediabetic neuropathy, inflammation via inhibition of TXNIP and NLRP3-inflammasome activation | |
[10], [105] | Verapamil, 100 mg/kg | Po daily | STZ- and HFD-obesity model | Inhibit TXNIP expression and restore beta-cell function, improve glucose level in STZ- and HFD-obesity model |
[100] | Metformin | STZ-diabetes mouse | Suppressed TXNIP/NLRP3 inflammasome activation, reduced cell apoptosis in adipose tissue | |
[99] | Metformin | ApoE-/- + STZ mice | Inhibited TXNIP/NLRP3 inflammasome activation, and suppressed diabetes-accelerated atherosclerosis in apoE-/- mice | |
[101] | Ezetimibe (250 µg, 500 µg, 1 mg) | 1 hIntra-nasal | Rat model middle cerebral artery occlusion | Improved infarct volume, neurological outcome Increased activation of AMPK, modulated oxidative stress, microglial activation and TXNIP/NLRP3 activation |
[103] | SRI-37330 | Po daily | STZ-mouse model and obesity-induced (db/db) diabetes | Inhibited glucagon secretion and function, reduced hepatic glucose production, and reversed hepatic steatosis |
[105] | W2476, 200 mg/kg | Po daily | STZ- and HFD-obesity model | Inhibit TXNIP expression and restore beta-cell function, improve glucose level in STZ- and HFD-obesity model |
[34] | GW0742 (25 μg/kg; intranasal) | 1 h/ 24 h | Rat pups with hypoxic ischemia | GW0742 significantly reduced the activation of TXNIP/NLRP3 inflammasome, pro-inflammatory microglia |
Table 3 Summary of the in vivo studies
Ref. | Duration of Studies | Insult | TXNIP | NLRP3 | CASP-1 | IL-1β | TNF-a | NFKB | Casp-3 | NY | Other markers |
Mohamed et al[2], 2015 | Rat retina, 10 wk | HFD | + | + | + | + | + | + | + | + | Acellular capillaries |
Coucha et al[11], 2017 | Mouse retina, 8 wk | HFD | + mRNA | ER-stress, | |||||||
Mohamed et al[41], 2020 | Mouse retina, 8 wk | HFD | + | - | - | + | Leukostasis, acellular | ||||
Mohamed et al[58], 2018 | Mouse liver, 8 wk | HFD | + | + | + | + | Trend | + | TLR2 signal +, fibrosis | ||
Elshaer et al[40], 2017 | Mouse sk. Muscle, 8 wk | HFD | + | - | + | + | + | Systemic IL-1b, vascular | |||
Coucha et al[33], 2019 | Mouse-retina, 1-3 d, 14 d | I/R | + protein + mRNA | + | + | + | + | Acellular | |||
El-Azab et al[19], 2014 | Mouse-retina, 1-d | NMDA | + | + | + | + | + | Acellular | |||
Al-Gayyar et al[7], 2011 | Rat-retina, 1-d | NMDA | + | + | + | + | + | + | Neurode | ||
Ishrat et al[80],2015 | Mouse; Brain | Embolic | + | + | + | + | + | + | + | Neurological function, cerebral blood | |
Ismael et al[94], 2021 | Mouse brain, 24 h | Stroke+ HG | + | = | + | + | + | + trend | Hemorrhagic transformation | ||
Wang et al[24], 2020 | Rat brain, 7-d | Stroke | + | + | + | + | + | Pyroptosis, | |||
Liu et al[97], 2020 | Rat brain, 7 d | Stroke | + mRNA + protein | + | - | + | + | Neurological | |||
Gamdzyk et al[34], 2020 | Rat pups brain, 24 h | Hyp-oxia | + | + | + | + | Microglial activation, | ||||
Ding et al[21], 2016 | Rat brain, 14 d | Throm | + | + | + | + | + | ER- stress neural pyroptosis | |||
Yin et al[29], 2021 | Rat brain, 72 h | Stroke | + | + | + | + | Microglial activation, | ||||
Tian et al[81], 2012 | Rat brain, 24 h | Stroke | + | MAPK activa | |||||||
Guo et al[3], 2018 | Mice, 72 h | Stroke | + | + | + active | + | Elevated ER | ||||
Hou et al[102], 2018 | Rat brain, 24 h | Stroke | + | + | + | Nrf2 and NL | |||||
Cao et al[43], 2016 | Mice brain, 24 h | Stroke | + | + | + | Neuro. deficit, | |||||
Guo et al[3], 2016 | Rat brain, 24 h | HG + stroke | + | + | + | + | Hemorrhagic transformation | ||||
Hua et al[83], 2015 | Rat brain, 24 h | Stroke | + | + | + | Neurological deficit | |||||
Wang et al[98], 2015 | Rat brain | Stroke | + | + | + | + | PPARγ, nega | ||||
Li et al[20], 2015 | Rat brain, 24 h | Stroke | + | + | + | + | ER stress me |
Table 4 Summary of the in vitro Studies
Ref. | Cell type | Insult | TXNIP | NLRP3 | CASP-1 | IL-1β | TNF-a | NFKB | Casp-3 | Other markers |
Mohamed et al[2], 2015 | EC | Palmitate | + | + | + | + | + | IL1-b in cell lysate and CM Adhesion Molecules | ||
Mohamed et al[41], 2020 | EC | TXNIP++ | + | trend | + | + | Adhesion Molecules | |||
Coucha et al[11], 2017 | Muller | Palmitate | + protein + mRNA | trend | trend | + | IL1-b in cell lysate | |||
Coucha et al[33], 2019 | Muller | Hypoxia | + mRNA | trend | + | + | IL-1b in cell lysate | |||
El-Azab et al[19], 2014 | NMDA | + | + | + | + | + | IL1-b in CM | |||
Gamdzyk et al[34], 2020 | P12 cells | OGD | + | + | + | Cell death, miR-17-5p | ||||
Tian et al[81], 2012 | Primary rat cortical neuron | OGD | + | Oxidative stress and activation of MAPK | ||||||
Liu et al[97], 2020 | Primary rat neurons | OGD | + | + | + | + | TXNIP NLRP3 | |||
Guo et al[3], 2018 | SH-SY-5Y cells | OGD | + | + activity | + | Activation of ER stress | ||||
Cao et al[43], 2016 | bEnd.3 | OGD | + | + | + | MAPK activation, EC-damage |
- Citation: Mohamed IN, Li L, Ismael S, Ishrat T, El-Remessy AB. Thioredoxin interacting protein, a key molecular switch between oxidative stress and sterile inflammation in cellular response. World J Diabetes 2021; 12(12): 1979-1999
- URL: https://www.wjgnet.com/1948-9358/full/v12/i12/1979.htm
- DOI: https://dx.doi.org/10.4239/wjd.v12.i12.1979